What the study found
One hundred two people with heart failure were randomized to usual medicines with or without CoQ10. Twenty-four-hour Holter monitoring and other assessments were performed before treatment and at six and twelve months. [1]
At twelve months, AF episodes were reported in three CoQ10 participants and twelve controls. The small number of events and intermittent monitoring limit how completely the study can characterize rhythm burden. [1]
What remains unanswered
The abstract does not establish a matching placebo or blinding. Its findings concern adjunct treatment in heart failure, not every person with AF. Funding and conflicts were not established, and no stroke-prevention or anticoagulant-replacement conclusion follows. [1]
A hypothetical distinction
Imagine two brief monitoring windows record different event counts. Those observations matter, but they do not continuously measure every rhythm event between visits.
| Detail | Interpretation |
|---|---|
| 102 patients | Heart-failure population |
| Intermittent Holter | Limited observation windows |
| Stroke prevention | Not established |

Sources for this article
- Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure - PubMed
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.